Prognostic Stage 2 Breast Cancer AJCC v8 Completed Phase 2 Trials for Mirvetuximab soravtansine (DB12489)

Also known as: Prognostic Stage II Breast Cancer AJCC v8

IndicationStatusPhase
DBCOND0140767 (Prognostic Stage 2 Breast Cancer AJCC v8)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03106077Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerTreatment